News

Guyana Chronicle1h
WHO urges rollout of first long-acting HIV prevention jab
A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...
AARP18h
What Older Adults Need to Know About a New HIV Medication
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
Managed Healthcare Executive21h
Indirect Comparison Shows Apretude and Yeztugo Have Similar Efficacy | IAS 2025
Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...
Applied Clinical Trials Online17h
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...
Bhekisisa23h
SA gets R520-million to buy the twice-a-year anti-HIV jab — but there’s a snag
SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...
Managed Healthcare Executive2d
Lenacapavir’s Next Step: Turning Approval Into Access | IAS 2025
The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...